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Abstract
Multiple myeloma is a hematological cancer of plasma B-cells and remains incurable. Two major
subtypes of myeloma, hyperdiploid (HMM) and non-hyperdiploid myeloma (NHMM), have
distinct chromosomal alterations and different survival outcomes. Transcription factors (TrFs)
have been implicated in myeloma oncogenesis but their dysregulation in myeloma subtypes are
less studied. Here we develop a TrF-pathway co-expression analysis to identify altered co-
expression between two sample types. We apply the method to the two myeloma subtypes and the
cell cycle arrest pathway, which is significantly differentially expressed between the two subtypes.
We find that TrFs MYC, NF-κB and HOXA9 have significantly lower co-expression with cell
cycle arrest in HMM, co-occurring with their over-activation in HMM. In contrast, TrFs ESR1,
SP1 and E2F1 have significantly lower co-expression with cell cycle arrest in NHMM. SP1 ChIP
targets are enriched by cell cycle arrest genes. These results motivate a cooperation model of
ESR1 and SP1 in regulating cell cycle arrest, and a hypothesis that their over-activation in NHMM
disrupts proper regulation of cell cycle arrest. Co-targeting ESR1 and SP1 shows a synergistic
effect on inhibiting myeloma proliferation in NHMM cell lines. Therefore, studying TrF-pathway
co-expression dysregulation in human cancers facilitates forming novel hypotheses towards
clinical utility.
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Introduction
Multiple myeloma (myeloma or MM) accounts for 10% of all hematological cancers1. It is a
cancer of plasma B cells that undergoes monoclonal expansion in bone marrow, leading to
symptoms such as kidney failures, frequent infections, anemia and bone fractures. The past
decade has seen effective new treatment of MM such as proteasome inhibitors, but MM is
still incurable and the median survival time of myeloma patients is 7–8 years2.
Chromosomal alterations revealed by cytogenetics and genomics techniques divide MMs
into two major subtypes: hyperdiploid multiple myeloma (HMM, 55–60% of MM) and non-
hyperdiploid multiple myeloma (NHMM, the rest of MM). HMM usually contains trisomies
of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21 and lacks translocation events; while NHMM
is often associated with one-copy deletion of chromosome 13 and translocations involving
the immunoglobulin heavy chain (IgH) locus at 14q32, such as t(4;14), t(11;14), and
t(14;16)2, 3. The survival outcome of HMM patients is better than that of NHMM2, 4.
Therefore, it’s of biological and clinical interest to ask whether and how the different
genomic alteration profiles in the two subtypes contribute to MM pathogenesis and response
to treatments.
Genome-wide gene expression profiling has contributed to the understanding of
transcriptional alterations in myeloma and its subtypes compared to normal plasma B cells.
Dysregulation of cell cycle-related genes Cyclin D1, D2 or D3 by translocation or
hyperdiploidy, has been found to be a unifying and early pathogenic event in MM5, 6. Chng
and colleagues have compared the gene expression between HMM and NHMM and found
that HMM is associated with the activation of NF-κB, MYC and MAPK pathways, whereas
the NHMM is associated with oncogene-activating translocations7, 8. Agnelli and colleagues
have reported that differentially expressed genes and pathways between HMM and NHMM
are mainly involved in protein biosynthesis, transcriptional machinery and oxidative
phosphorylation9. Most of these genes locate in the trisomy chromosomes of HMM and
therefore could represent direct dosage effect of copy number gains. However, genomic
alterations could also have indirect effect in gene expression through dysregulating
transcription factors (TrFs) and members in signaling pathways10–12. In this project we
study how dysregulated TrFs in MM contribute to such indirect effect.
TrFs are the downstream effectors of signaling pathways within cells that receive growth
and other signals from microenvironment. They also survey internal cellular homeostasis
and make decisions on cell survival and proliferation13. Consequently, mutations in TrF
genes or dysregulation of TrFs could play significantly roles in cancer pathogenesis and
drug resistance. In myeloma, over-activation of TrFs such as NF-κB and MYC is frequently
observed and targeted as potential therapy14, 15. Several approaches have been developed to
infer TrF dysregulation from global gene expression profiles. Gene set enrichment analysis
identifies the enrichment of the target genes of a TrF in differentially expressed genes
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tbetween two biological conditions as indication for the TrF’s own dysregulation16. Co-
expression patterns between genes can also be analyzed to infer network changes between
biological conditions17–20.
In this study, we hypothesize that between the HMM and NHMM myeloma subtypes,
distinct TrF pathways dysregulate converging cancer pathways. This hypothesis motivates
us to develop a TrF-pathway co-expression analysis method to identify TrFs that correlate
with the cell cycle arrest pathway differently between the two subtypes. From this analysis,
we find robust, subtype-specific co-expression patterns between TrFs and the cell cycle
arrest pathway. These results support a novel cooperation model of ESR1, SP1 and E2F1 on
dysregulating cell cycle arrest in NHMM and their potential therapeutic implication. We
then validate this prediction by drug combination treatments using four NHMM cell lines.
Materials and Methods
Gene expression profiling data sets
We used the following public GEO data sets of myeloma gene expression profiling.
GSE64777 contains 70 expression samples of HMM and 70 samples of NHMM.
GSE1978421 contains 201 samples with HMM status out of 320 samples. HMM and
NHMM status are measured by FISH in these two studies. Samples with ambiguous HMM
status such as those with both FISH-measured trisomies and translocations were excluded
from our analysis. GSE636522 has 90 samples without information of HMM status. We
applied a KNN-based method to classify samples into HMM and NHMM by their
expression profiles23. The accuracy of this method is more than 85% when compared to
FISH-based and copy number microarray-based HMM status. All the data sets were
normalized and processed by the RMA method of Bioconductor to obtain expression values.
We used a transcription factor list containing nearly 200 common TrFs24, which is
downloaded from the UCSC Genome Browser database.
The TrF-pathway co-expression algorithm
1. Paired t-test and correlation calculation—Paired t-test was used to compare the
overall expression change of cancer related pathways between the two subtypes of myeloma
(Figure 1A). Each pathway gene has a pair of average expression value across the samples
in the two subtypes, and the test assesses the overall expression difference of pathway genes
between the two subtypes of myeloma.
Next, we apply Spearman’s rank correlation to calculate the correlation coefficient between
TrF and each pathway’s genes in the HMM and NHMM subtypes respectively (Figure 1B).
Defined as Pearson’s correlation between rank-transformed values, Spearman’s correlation
can detect non-linear correlation and reduce bias caused by outlier samples.
2. Define Pattern Score to quantify TrF-pathway co-expression changes—In
the next step, we have developed a formula to measure the change of TrF-pathway
correlation pattern between the two myeloma subtypes. In the co-expression plot between a
TrF and pathway genes (Figure 2A and 2B), the X value and Y value of each point
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trepresents the co-expression coefficient of a TrF and a gene in HMM and NHMM,
respectively, rather than expression levels. Our analysis compares the co-expression
alteration between the two subtypes.
We then define a score for the scatterplot pattern based on individual pathway genes (x, y)
as:
Pattern Score = Sum of all blue points {Distance between (x, y) and the diagonal line *
sign(|y|-|x|) } * −log(p-value of Hotelling test)
The Hotelling p-value tests whether the correlation coefficients between the TrF and the
pathway genes (blue points in Figure 2A) are differently distributed compared to the
correlation coefficients between the TrF and all the other genes (black points). Hotelling's T-
squared test is a multivariate version of the t-test25 and tests for the difference between the
multivariate means of two populations. A significant p-value suggests that the TrF has a
different functional relationship with this pathway compared to all other genes. The distance
to the diagonal line of a point measures its degree of correlation coefficient change between
the two subtypes, while the sign indicates in which subtype the point has higher absolute
correlation with the TrF. For example, a gene point (x, y) in region A or B of Figure 2C has |
y|>|x|, so this gene has higher absolute correlation with the TrF in NHMM (the Y-axis
subtype) than in HMM (the X-axis subtype).
Pattern Score has larger absolute value when the scatterplot deviates from y=x (Figure 2E
and 2F) than when it is close to y=x (Figure 2D). The significance of the Pattern Score is
determined by permuting the subtype labels of the samples and comparing the observed
Pattern Score to the distribution of the maximal score obtained from 1000 permutations (in
the Bayesian model below we performed 100 permutations).
3. Linear regression to test the co-expression scatterplot’s deviation from y=x
—A typical co-expression plot between a TrF and pathway genes is shown in Figure 2A,
where blue points (pathway genes) and black points (the rest genes) represent the correlation
coefficient between a specific TrF and a gene in HMM subtype (X-axis) and NHMM
subtype (Y-axis). To detect the overall change of TrF-pathway co-expression between
HMM and NHMM, we also checked whether or not the slope is 1 for the blue points
(pathway genes) in Figure 2A. If the slope is significant different from 1, it indicates that the
co-expression of TrF and pathway genes has a global change between the two subtypes of
myeloma. We rotated the coordinates of all points by 45 degrees clockwise and then tested
whether the regression slope in the new scatterplot is 0. A significant p-value indicates the
change of TrF-pathway co-expression between the two subtypes.
4. Bayesian meta-analysis of multiple data sets—In the meta-analysis step, we used
a Bayesian method to pool information across multiple data sets and down-weight the results
specific to a single-data set26. Briefly, in each data set we first computed the correlation
coefficient r between a transcription factor and a pathway gene, and then converted r into a
standard normal statistic using Fisher’s r-to-z transformation, with associated variance
determined by sample size. Next, a hierarchical Bayesian model was used to combine the z
values from different data sets to arrive at the TrF-gene correlation coefficient pooled across
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tmultiple data sets. We followed the formulas in Choi et al. 200526. This meta-analysis was
also performed on the null data generated from 100 permutations of sample group labels to
assess the statistical significance of identified top TrFs.
Drug treatment, cell proliferation assay and isobologram analysis
U266, MM1S and RPMI-8226 myeloma cells were obtained from the American Type
Culture Collection (ATCC). OPM2 were obtained from the German collection of
microorganisms and cell cultures (DSMZ). The INA6 cell line was provided by Renate
Burger. All the cell lines are NHMM-characterized subtype: INA-6 is a IL-6-dependent
human myeloma cell line27, while U266, OPM-2, RPMI-8226 and MM1S contain Ig locus
translocation28, 29.
The MM cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum.
In the combination treatment experiments, cells were cultured with or without Tamoxifen
(TMX) in the absence or presence of Terameprocol (TMP) for 48 hours. MM cell
proliferation was measured by DNA synthesis through [3H]thymidine (Perkin-Elmer)
incorporation assay, as previously described30. All experiments were carried out in
triplicates.
The interaction between TMP and TMX was analyzed using the CalcuSyn software program
(Biosoft, Ferguson, MO), which is based on the Chou-Talalay method31. When combination
index (CI) = 1, it represents the conservation isobologram and indicates additive effects. CI
< 1 indicates synergism and CI > 1 indicates antagonism.
Results
Motivations for studying the cell cycle arrest pathway and its co-expression with TrFs
Using the Chng data set and major cancer pathways32, 33, we found that the cell cycle arrest
pathway is significantly up-regulated in HMM compared to NHMM (Figure 1A), and is up-
regulated in both subtypes compared to normal plasma cells. We also observed co-
expression changes between TrFs and their target genes. For example, the co-expression
pattern between a TrF SP1 and cyclin-dependent kinase CDK2, a transcriptional target of
SP134, is much stronger in HMM than in NHMM (Figure 1B). The co-expression analysis
can detect such changes that are not obvious from gene-wise differential expression analysis
of either SP1 or CDK2 (p-value is 0.11 and 0.053, respectively). These results and existing
knowledge of cell cycle’s dysregulation in myeloma motivated us to develop a TrF-pathway
co-expression analysis method to identify TrFs that differently correlate with the cell cycle
arrest pathway between the two subtypes.
TrF-pathway differential co-expression analysis
We developed a statistical analysis method to detect co-expression changes between
transcription factors and genes in cancer-related pathways. Figure 1C outlines the analysis
pipeline. Differentially expressed, cancer-related pathways between two biological
conditions were first identified. We next scored TrFs that have significant co-expression
changes with pathways of interest between two sample conditions. This method ranks TrFs
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tby the degree of TrF-pathway co-expression changes between the two conditions. Finally,
permutation of sample group labels was used to generate null data sets and call significantly
TrFs.
We used this pipeline to ask what TrF’s co-expression with the cell cycle arrest pathway has
significant difference between the two myeloma subtypes, HMM and NHMM. The Pattern
Score (defined in Methods) measures whether a TrF-pathway pair has an overall different
correlation pattern between the two subtypes. If the pathway genes (blue points in Figure 2)
and a TrF have largely unchanged co-expression between the two subtypes, the scatterplot
of blue points centers along the diagonal line (y=x) and the Pattern Score is close to zero
(Figure 2D). If the scatterplot has a slope far from 1, it indicates an overall change of TrF-
pathway co-expression between the two subtypes and the Pattern Score will be much larger
or smaller than 0 (Figure 2E and 2F). We also used a linear regression to test whether the
pattern has significant deviation from the diagonal line (see Methods). The p-value of this
test is 0.896, < 2.2e-16 and 3.7e-08 for the patterns in Figure 2D, E, F, respectively.
TrFs involved in IL-6 and MAPK signaling have significantly lower co-expression with cell
cycle arrest genes in HMM
We first applied the TrF-pathway co-expression analysis on the data set GSE64777 and
compared our findings to those in the original study for evaluation of the co-expression
analysis. Table 1 lists top-ranked TrFs that have significantly lower co-expression with cell
cycle arrest genes in HMM compared to NHMM, including HOXA9, MYC and NF-κB
family member c-Rel (REL). Also from Table 1, CEBPB and STAT3 are involved in the
IL-6 pathway, and NF-κB, MYC and ATF2 are involved in the MAPK signaling
pathway35, 36. Both pathways promote myeloma initiation and progression2. Furthermore,
RELA (p65, an NF-κB subunit, score=−138) and FOS (an IL-6 pathway member; score=
−141) also have high scores but their permutation p-values are not as significant. These two
TrFs also associate with the MAPK signaling pathway and the IL-6 pathway. Our co-
expression analysis arrived at findings consistent with the original study of GSE6477, which
has reported that MYC, NF-κB, MAPK and IL-6 pathways are over-expressed in HMM than
in NHMM7.
ESR1, SP1 and E2F1 have significantly lower co-expression with cell cycle arrest genes in
NHMM
In contrast to HMM, the transcriptional dysregulation in NHMM has been less studied,
although the translocation events are more associated with NHMM. Table 2 lists top-ranked
TrFs that have significantly lower co-expression with cell cycle arrest genes in NHMM
compared to HMM. Among them, ESR1 (Estrogen receptor alpha), SP1 and E2F1 are three
TrFs known to influence cellular processes that include proliferation and apoptosis37–39.
These results have not been reported by the original study of GSE64777.
Bayesian meta-analysis of multiple data sets improves the robustness of analysis
We next asked whether these findings are specific to one data set (GSE6477) or general in
myeloma. We added two other myeloma expression data sets that have both HMM and
NHMM samples, GSE636522 and GSE1978421. We used a Bayesian hierarchical model to
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tcompute correlation coefficients between TrFs and genes by pooling across data sets and
weighting their respective sample sizes26. The meta-analysis down-weights TrF-pathway co-
expression patterns specific to one data set, even if this pattern may be significant in the data
set (Figure 3A); and enhances the patterns consistent across data sets but may not be
significant in any one data set (Figure 3B). Table 3 lists the TrFs with significantly different
co-expression with cell cycle arrest genes between HMM and NHMM after pooling the
three data sets. Table 3B and Figure 3B show that both SP1 and ESR1 are still top-ranked as
having significantly lower co-expression with cell cycle arrest genes in NHMM compared to
HMM across different patient cohorts.
Cell cycle arrest genes are enriched by SP1 ChIP targets
Although co-expression analysis suggests regulatory role of SP1 on cell cycle arrest genes, it
cannot determine whether such regulation is direct or indirect. We next analyzed SP1 ChIP-
seq (chromatin immunoprecipitation followed by sequencing) data of GM12878, a
lymphoblastoid cell line from the ENCODE project, to check if SP1 targets are enriched by
cell cycle arrest pathway genes (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
encodeDCC/wgEncodeHaibTfbs). An enrichment supports a direct regulatory role of SP1 on
the cell cycle arrest pathway. There are 2150 genes whose transcript starting site (TSS) is
within 3 kb upstream or downstream of the top 5000 SP1 peaks. Among the 310 cell cycle
arrest genes we used in the co-expression analysis (Suppl. Table 1), 85 have strong SP1
binding peaks near their TSS regions (27%). Therefore, cell cycle arrest genes are enriched
by SP1 targets (p-value = 3.86e-08) in this B lymphocyte cell line. Since myeloma cells
come from the B cell lineage, SP1 dysregulation is likely to directly affect the gene
expression of cell cycle arrest pathway in myeloma.
We then analyzed an ESR1 ChIP-seq data in a breast cancer cell line MCF-7 (GSE25021),
since ESR1 ChIP data are not available for B cells. There is no enrichment of ESR1 targets
in cell cycle arrest genes. However, ESR is known to regulate genes indirectly through
interactions with Sp1 transcription factor40, supporting its possible indirect regulation of the
cell cycle arrest pathway.
A model of cooperation between SP1 and ESR1 on regulating cell cycle arrest
Based on these results and literature evidences, we proposed a model of cooperation
between SP1 and ESR1 on regulating cell cycle arrest and their over-activation in NHMM
(Figure 4). Over-activation of ESR1 in myeloma cells induces MAPK/ERK pathways
through c-SRC41 (Step 1 in Figure 4), which in turn activate SP1, leading to increased
expression of the downstream factor E2F1 (Step 2). Furthermore, both SP1 and ESR1
regulate Cyclin D1 (CCND1)42, 43, which is frequently abnormal in myeloma5, and lead to
cell cycle progression (Step 3). This model suggests a combination therapy to inhibit both
SP1 and ESR1 activities to overcome the limitations of single-drug treatments that inhibit
either SP1 or ESR1 alone. For example, anti-estrogens therapy, especially the most
commonly used tamoxifen, has major limitations including its partial agonist activity and
constitutive or acquired resistance44. Tamoxifen resistance has been shown to be a result of
increased ERα (product of ESR1) and Sp1 interaction that enhances the expression of
E2F145, 46.
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tSynergistic growth inhibition effect of co-targeting SP1 and ESR1 in myeloma cells
The cooperation model predicts an approach to preventing cell proliferation by intervening
SP1 and ESR1’s dysregulation in myeloma cells. We investigated the effect of co-targeting
SP1 and ESR1 proteins on MM cell growth. Our recent work showed that Sp1 plays a
regulatory role in multiple myeloma cell growth and survival, and it can be inhibited by the
anti-MM activity of TMP, a small molecule that specifically competes with Sp1-DNA
binding in vitro and in vivo30. In addition, tamoxifen (TMX), an antagonist of estrogen
receptor, has been shown to induce growth arrest and apoptosis in multiple myeloma cell
lines37, 44. In our combination treatment experiments, NHMM cells were cultured for 48
hours with TMX (0.5 and 20 µM), TMP (5 and 10 µM) or their combinations, and cell
proliferation was measured by [3H]thymidine uptake at 48 hours. In four of the five cell
lines treated, all combinations of TMX and TMP resulted in significant (p-value < 0.05) and
synergistic anti-proliferative effect (Figure 5), except the treatment TMP 5 uM and TMX 20
uM for the OPM2 cell line. For example, treatment of TMX at 0.5 and 20 µM alone triggers
10% and 40% growth inhibition in U266 cells, respectively (Figure 5A), which was further
enhanced to 40% (combination index = 0.68) and 70% (combination index = 0.5) by
combined treatment with TMP at 5 µM (Figure 5C, table rows in blue). In MM1S cells, a
synergistic effect was achieved only at 72 hours (data not shown).
Discussion
This study starts from the two myeloma subtypes that have distinct and characteristic
genomic alterations, which may have been selected during cancer cell evolution and lead to
different paths to oncogenesis and differential survival outcomes. We hypothesize that the
dysregulation of TrFs can induce co-expression alteration between a TrF and the genes it
regulates directly or indirectly. Because the cell cycle arrest pathway has significant
expression level changes between the HMM and NHMM subtypes among cancer-related
pathways, and that cell cycle dysregulation could be a common pathogenic mechanism in
myeloma5, we have focused on the cell cycle arrest pathway. We have developed a co-
expression analysis method to identify TrF-pathway co-expression dysregulation in two
major myeloma subtypes. Our analysis has revealed specific TrFs that could be dysregulated
in each myeloma subtype which in turn may lead to their reduced regulation of cell cycle
arrest. Based on these results and literature evidences, we have proposed a cooperation
model between TrFs SP1 and ESR1 in contributing to cell cycle dysregulation in myeloma.
Our experiments show that combination treatment targeting both TrFs has synergistic effect
on growth inhibition of myeloma cell lines, and therefore support the proposed model.
Compared to the traditional method of differential expression analysis followed by gene set
enrichment of pathways or TrF target sets, our co-expression method may identify TrFs
whose targets are not differentially expressed but are differentially regulated by the TrFs,
which are biologically relevant and complementary results to existing methods. In addition,
the co-expression analysis can identify TrFs that dysregulate downstream genes in indirect
ways, while TrF target enrichment analysis cannot. For example, using predicted TrF target
information based on TRANSFAC24, we identified only a few TrFs, whose target genes are
enriched in cell cycles arrest genes and which are also differentially expressed between
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tHMM and NHMM in the GSE6477 dataset, including MYC, MYB, CREB1, E2F3 and
USF2 (Suppl. Table 4). This is in contrast to many TFs that we identified to differentially
regulate cell cycle arrest genes between the two myeloma subtypes (Table 1 and 2). In
particular, our analysis identified ESR1’s dysregulation in NHMM. ESR1 had been reported
to regulate genes through indirect mechanisms such as by interacting with cofactors AP-1
and Sp140, and our ChIP-seq analysis of ESR1 binding peaks showed no enrichment of cell
cycle arrest genes. Finally, although TrF target enrichment analysis may suggest direct
regulation, it is restricted to available target prediction or ChIP-seq data; while the co-
expression does not require such information.
The TrF-pathway co-expression analysis has revealed dysregulated pathways that are
consistent with previous analysis of HMM. Both our analysis and the original study of
GSE6477 have found MYC and NF-κB pathways as dysregulated in HMM. In addition, we
have identified HOXA9 as the top TrF dysregulated in HMM due to its reduced co-
expression with cell cycle arrest genes both in the GSE6477 data and in the Bayesian meta-
analysis (Tables 1 and 3A). Although HOXA9 was not identified in Chng et al.7, it has
recently been suggested as a candidate oncogene in myeloma by a genome-wide sequencing
study47. HOXA9 is a transcription factor regulating gene expression, morphogenesis and
differentiation48. A translocation event causing a fusion between HOXA9 and NUP98 has
been associated with myeloid leukemogenesis49, 50. In MM, it has high expression level in
patients lacking IgH translocations47, agreeing with that HOXA9 has a higher expression in
HMM than in NHMM in the three data sets we analyzed (p-values of 0.076, 0.019, 0.008).
HOXA9-depleted cells show a competitive growth disadvantage47, suggesting its
expression-related carcinogenesis role in myeloma. Therefore, HOXA9 with higher
expression level in HMM is associated with oncogenesis, co-occurring with our analysis
results of HOXA9’s reduced co-expression with cell cycle arrest pathway in HMM.
We have also identified TrFs SP1, ESR1 and E2F1 as having significantly lower co-
expression with the cell cycle arrest pathway in NHMM compared to HMM (Tables 2 and
3B). SP1 regulates a variety of processes such as cell growth, apoptosis, differentiation and
immune responses38. It also mediates the transcription of cyclins and cyclin-dependent
kinases43, 51. It has been recently shown to play an important regulatory role in MM cell
growth and survival30. MM cells display increased SP1 protein (Sp1) nuclear levels and
DNA binding activity compared to normal cells, and their interaction with bone marrow
stromal cells (BMSC) lead to Sp1 activation via induction of the ERK signaling pathway30.
Moreover, genetic inhibition of Sp1 with siRNA and shRNA technologies and
pharmacological inhibition with a specific Sp1 inhibitor significantly reduced MM cell
growth and survival in vitro and in vivo30. Estrogen receptors (ESR1 and ESR2) are nuclear
receptors that are activated by the hormone estrogen and then bind to DNA to regulate
downstream genes52. They are over-expressed in 70% of breast cancer samples, and these
ER-positive cancers respond to estrogen receptor antagonist such as tamoxifen46, 53. Studies
show that MM cells often express and over-activate estrogen receptors (ER), and selective
estrogen receptor modulators induce G1-S cell cycle arrest and apoptosis in MM
cells44, 54, 55. Moreover, ESR1 interacts with Sp1 to regulate transcription of downstream
genes, including E2F1, a key regulator of the G1-S cell cycle checkpoint 46, 56.
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effect and minimizing drug resistance31. Based on the TrF-pathway results and literature
reviews, we have proposed a cooperation model of SP1 and ESR1’s roles in regulating cell
cycle arrest and their dysregulation in NHMM. A combination treatment targeting both SP1
and ESR1 has synergistic growth inhibition effect on NHMM cell lines. These result support
the SP1-ESR1 cooperation model and point to further experimental follow-up.
There are areas for further improvement on this study. First, since myeloma is a cancer of
bone marrow, no normal bone marrows are available in large numbers for comparative
expression profiling. Due to small sample size or lack of normal samples in the data sets
used, we have not included normal samples in the analysis. In this study, we have used the
evidence that TrFs such as MYC and HOXA9 are both over-activated in HMM and have
lower co-expression with the cell cycle arrest pathway to associate a TrF’s lower co-
expression in a subtype with its dysregulation in the subtype. Comparing MM subtypes with
normal samples in future studies using the co-expression analysis could help confirm this
association. Comparing to normal samples can also reveal TrFs that are commonly
dysregulated in both subtypes. The second limitation is the use of TrFs that are based on
TRANSFAC TrFs, which are well studied58. Although this helps interpreting these TrFs’
roles in cell cycle pathways and designing experimental validation, we may miss novel
mechanisms involving TrFs not in the list. Expanding the analysis to predicted TrFs based
on their DNA-binding domains will alleviate this limitation59. The third limitation is that
when a TrF has significant co-expression with a gene in a pathway, relationship between the
TrF and the gene may not be causal or direct. Other genetic regulators may regulate both the
TrF and the gene, or the TrF regulates the gene via intermediate regulators. We have
checked the ChIP-seq based gene targets of SP1 and found that they are enriched by cell
cycle arrest genes. This lends support that SP1 directly regulates many cell cycle arrest
genes, but wet experiments are needed to validate these predictions. Bioinformatic
algorithms such as ARACNE may be used to better distinguish direct and indirect co-
expression relationship60. These limitations point to areas to improve the TrF-pathway co-
expression analysis for better understanding of regulatory alterations in cancer. Another
interesting direction is to use co-expression signatures as biomarker for patient prognosis57.
The TrF-pathway co-expression analysis code is available at http://chenglilab.weebly.com/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) Differential expression of cancer-related pathways between HMM and NHMM.
The bars show the gene counts (y-axis) vs. pathways ordered by the number of genes (x-
axis). The gene lists are downloaded from the Gene Ontology database. P-values on the top
of the bars are computed from paired t-test using each pathway gene’s average expression in
HMM and in NHMM as paired data points. Data set used: GSE6477.
(B) Co-expression between TrF SP1 and a cell cycle gene CDK2 in HMM and NHMM.
The gene expression values of SP1 (y-axis) is plotted against that of CDK2 (x-axis) for
HMM samples (left) and for NHMM samples (right). The correlation coefficient is stronger
in HMM. Both genes are not significantly differentially expressed between HMM and
NHMM (CDK2, p-value=0.053, SP1, p-value=0.11). Data set used: GSE6477.
(C) Overview of the TrF-pathway co-expression analysis. Using gene expression
profiling data, we identify differentially expressed cancer pathways between two biological
conditions. Next, we use a formula to score TrFs for their differential co-expression patterns
with pathways of interest between the two conditions. Permutation of sample group labels
was used to assess the statistical significance of top-ranked TrFs.
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tFigure 2. Scoring significant TrF-pathway co-expression changes between two myeloma
subtypes
Key ideas are illustrated using GSE6477, a myeloma expression data set that compares
global gene expression differences between HMM and NHMM. (A) The co-expression
scatterplot between a TrF (COMP) and genes. Each point stands for the correlation
coefficients between the TrF and a gene in HMM samples (X-axis) and in NHMM samples
(Y-axis). Blue: genes in the pathway of interest (cell cycle arrest); black: all other genes. (B)
A cartoon version of (A). Blue points stand for cell cycle arrest genes while black ones stand
for other genes. The point (X1, Y1) indicates a gene that has respective correlation
coefficients with the TrF in HMM (X1) and NHMM (Y1). The blue arrow stands for the
distance between (X1, Y1) and the diagonal line, Y=X. (C) Two diagonal lines divide the
correlation space into four regions. For the points (genes) in regions A and B, the absolute
Y-axis value is larger than the absolute X-axis value. The opposite is true for the points in
regions C and D. Panel C–E: Three typical TrF-pathway co-expression patterns. (D) The
TrF COMP has no significant co-expression changes with cell cycle arrest genes between
HMM and NHMM. (E) SP1 has a lower overall correlation with the pathway genes in
NHMM (Y-axis) than in HMM (X-axis). (F) MYC has a lower overall correlation in HMM
(X-axis) than in NHMM (Y-axis).
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tFigure 3. The co-expression patterns of TrFs AHR and ESR1 in individual data sets and in the
meta-analysis
Meta-analysis averages out conflicting patterns in (A) and strengthens consistent patterns in
(B). (A) The TrF AHR does not have a robust co-expression alteration between HMM and
NHMM across the three individual data sets. The red and green dots represent two pathway
genes and their correlation coefficients with the TrF. Because the coefficients of the same
genes are quite different in the three data sets, the meta-analysis does not lead to a
significant Pattern Score. (B) ESR1 has a robust co-expression alteration between HMM and
NHMM across the three data sets. Most pathway genes such as those highlighted by the red
and green dots remain at similar correlation coefficient positions in the three data sets, so the
meta-analysis leads to a significant Pattern Score.
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tFigure 4. A model of cooperation between SP1 and ESR1 on regulating cell cycle arrest and their
over-activation in NHMM
ESR1, SP1 and their target E2F1 all have significantly lower co-expression with the cell
cycle arrest pathway in NHMM compared to HMM. See Discussion for details. Blue arrows
refer to literature-supported regulation in breast cancer, and red arrows in myeloma. “+p”
stands for phosphorylation. Black dotted arrows indicate indirect regulation. Red and blue
crosses and corresponding downward thick arrows indicate literature-supported knock-down
of upstream genes or TrFs and the corresponding effects in reducing downstream genes’
activity or expression in breast cancer (blue) and in myeloma (red).
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tFigure 5. Synergistic growth inhibitory effect of Sp1 inhibitor TMP and ESR1 antagonist
tamoxifen (TMX) on MM cells
Cell proliferation is measured as percentage of untreated cells at 48 hours for four different
MM cell lines: (A) U266, and (B) INA6, RPMI-8226 and OPM2. Data are means ± SD (n =
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(Fa) for the combinations of TMX and TMP are shown in the tables. CI < 1, CI = 1, CI
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